AN2 Therapeutics Inc
NASDAQ:ANTX

Watchlist Manager
AN2 Therapeutics Inc Logo
AN2 Therapeutics Inc
NASDAQ:ANTX
Watchlist
Price: 1.17 USD -2.5% Market Closed
Market Cap: 32.1m USD

Relative Value

There is not enough data to reliably calculate the relative value of ANTX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ANTX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
-1.1
Median 5Y
-2.4
Industry
21.6
Forward
-1.1
vs History
vs Industry
Median 3Y
-1.2
Median 5Y
-3
Industry
16.5
vs History
vs Industry
Median 3Y
-1.2
Median 5Y
-3
Industry
22.5
vs History
74
vs Industry
74
Median 3Y
0.7
Median 5Y
1
Industry
2.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
12
vs Industry
53
Median 3Y
0.5
Median 5Y
-0.5
Industry
13
vs History
12
vs Industry
51
Median 3Y
0.5
Median 5Y
-0.5
Industry
16.6
Forward
0.8
vs History
4
vs Industry
54
Median 3Y
0.6
Median 5Y
-0.7
Industry
15.8
vs History
4
vs Industry
41
Median 3Y
0.6
Median 5Y
-0.7
Industry
19.1
vs History
vs Industry
55
Median 3Y
-3.2
Median 5Y
-3.2
Industry
1.9

Multiples Across Competitors

ANTX Competitors Multiples
AN2 Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
AN2 Therapeutics Inc
NASDAQ:ANTX
31.6m USD 0 -0.9 0.8 0.8
US
Eli Lilly and Co
NYSE:LLY
993.4B USD 16.7 54 36.2 38.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
508.5B USD 5.5 20.2 16.5 21.5
CH
Roche Holding AG
SIX:ROG
256.1B CHF 4.2 27.2 11.6 13.6
UK
AstraZeneca PLC
LSE:AZN
209.1B GBP 4.8 29.8 108.1 158.3
CH
Novartis AG
SIX:NOVN
206.4B CHF 4.6 18 11.4 14.8
US
Merck & Co Inc
NYSE:MRK
243.7B USD 3.8 12.8 9.1 10.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.5 9.5 11
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
142.5B USD 2.3 14.5 7.4 10.1
P/E Multiple
Earnings Growth PEG
US
AN2 Therapeutics Inc
NASDAQ:ANTX
Average P/E: 23.7
Negative Multiple: -0.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.2
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.2
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.8
38%
0.8
CH
Novartis AG
SIX:NOVN
18
17%
1.1
US
Merck & Co Inc
NYSE:MRK
12.8
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.5
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
AN2 Therapeutics Inc
NASDAQ:ANTX
Average EV/EBITDA: 398.9
0.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.2
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.5
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.6
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.1
10%
10.8
CH
Novartis AG
SIX:NOVN
11.4
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.1
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.5
2%
4.7
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
AN2 Therapeutics Inc
NASDAQ:ANTX
Average EV/EBIT: 1 710.2
0.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.6
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.3
23%
6.9
CH
Novartis AG
SIX:NOVN
14.8
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.9
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
8%
1.3